<DOC>
	<DOCNO>NCT02596880</DOCNO>
	<brief_summary>The investigator treat 100 patient cirrhosis due hepatitis C sofosbuvir 400 mg daily , daclatasvir 60 mg daily weight-based ribavirin ( 1000 mg/d &lt; 75 kg , 1200 mg/d &gt; 75 kg , divide two daily dos ) 12 week calculate sustain viral response rate 12 week .</brief_summary>
	<brief_title>Sofosbuvir , Daclatasvir , Ribavirin Hepatitis C Virus ( HCV ) Cirrhotics</brief_title>
	<detailed_description>Cirrhosis due Hepatitis C present rather difficult treatment problem many tolerate interferon , previous standard treatment . The new direct acting antiviral provide patient new hope . One combination sofosbuvir ( SOF ) 400 mg daclatasvir ( DCV ) 60 mg give daily without weight-based ribavirin ( RBV ) 12 24 week . The current recommendation cirrhotics SOF/DCV/RBV 24 week recommendation base lack data short period . In order evaluate response rate combination SOF/DCV/RBV investigator decide treat 100 HCV cirrhotics combination 12 week . Subjects include genotype 1 3 patient , prevalent genotype Iran . Patients Model End stage Liver Disease ( MELD ) &gt; 20 exclude . The investigator calculate sustain viral response rate 12 week ( SVR12 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Positive qualitative HCV RNA test two occasion least 6 month apart Cirrhosis proven either : 1 . Liver biopsy , 2 . Liver elasticity &gt; 12 kilopascal ( KPa ) , 3 . Clinical certainty ( ascites , splenomegaly , small liver , low albumin , low platelet ) Renal failure ( eGFR &lt; 30 cc/min ) , MELD score &gt; 20 , Child 's C ( CTP score &gt; 12 ) , Heart rate &lt; 50/min , Taking amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Ribavirin</keyword>
</DOC>